<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Plasma <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a) [Lp(a)] concentrations are genetically determined, and hyper-Lp(a)-emia is an independent risk factor for <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>To study the implications of Lp(a) in cerebrovascular disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (DM), we examined plasma Lp(a) levels and molecular weights of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi>(a) [apo(a)] in 118 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, and 125 cases with DM </plain></SENT>
<SENT sid="2" pm="."><plain>Although mean Lp(a) concentrations were higher in those cases with atherothrombotic <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> than in those with brain <z:mp ids='MP_0001914'>hemorrhage</z:mp> and <z:e sem="disease" ids="C0333559" disease_type="Disease or Syndrome" abbrv="">lacunar infarction</z:e>, the difference was not statistically significant </plain></SENT>
<SENT sid="3" pm="."><plain>Lp(a) levels were significantly higher in the DM cases treated with insulin and in those treated with oral <z:chebi fb="0" ids="35526">hypoglycemic agents</z:chebi> than in those on diet therapy alone, suggesting that insulin and oral agents modulate apo(a) expression </plain></SENT>
<SENT sid="4" pm="."><plain>Lp(a) concentrations correlated significantly with the low-molecular-weight isoforms of apo(a) in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and DM groups </plain></SENT>
</text></document>